These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33449453)

  • 1. Preclinical efficacy and toxicity studies of a highly specific chimeric anti-CD47 antibody.
    Xu Z; Gao J; Yao J; Yang T; Wang D; Dai C; Ding Y
    FEBS Open Bio; 2021 Mar; 11(3):813-825. PubMed ID: 33449453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
    Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
    PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
    Narla RK; Modi H; Bauer D; Abbasian M; Leisten J; Piccotti JR; Kopytek S; Eckelman BP; Deveraux Q; Timmer J; Zhu D; Wong L; Escoubet L; Raymon HK; Hariharan K
    Cancer Immunol Immunother; 2022 Feb; 71(2):473-489. PubMed ID: 34247273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.
    Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y
    J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
    Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
    Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
    Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
    Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
    Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
    Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
    Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
    J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
    Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
    Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
    Gholamin S; Mitra SS; Feroze AH; Liu J; Kahn SA; Zhang M; Esparza R; Richard C; Ramaswamy V; Remke M; Volkmer AK; Willingham S; Ponnuswami A; McCarty A; Lovelace P; Storm TA; Schubert S; Hutter G; Narayanan C; Chu P; Raabe EH; Harsh G; Taylor MD; Monje M; Cho YJ; Majeti R; Volkmer JP; Fisher PG; Grant G; Steinberg GK; Vogel H; Edwards M; Weissman IL; Cheshier SH
    Sci Transl Med; 2017 Mar; 9(381):. PubMed ID: 28298418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint.
    Wu ZH; Li N; Mei XF; Chen J; Wang XZ; Guo TT; Chen G; Nie L; Chen Y; Jiang MZ; Wang JT; Wang HB
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile.
    Wang T; Wang SQ; Du YX; Sun DD; Liu C; Liu S; Sun YY; Wang HL; Zhang CS; Liu HL; Jin L; Chen XP
    J Transl Med; 2024 Mar; 22(1):220. PubMed ID: 38429732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
    Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
    Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein
    Wang Z; Hu N; Li X; Wang H; Ren C; Qiao C; Chen G; Wang J; Zhou L; Wu J; Zhang D; Feng J; Shen B; Peng H; Luo L
    Mol Pharmacol; 2021 Sep; 100(3):193-202. PubMed ID: 34315811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
    Peluso MO; Adam A; Armet CM; Zhang L; O'Connor RW; Lee BH; Lake AC; Normant E; Chappel SC; Hill JA; Palombella VJ; Holland PM; Paterson AM
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity.
    Qu T; Zhong T; Pang X; Huang Z; Jin C; Wang ZM; Li B; Xia Y
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.